Kapak Resmi

Advances in cancer biomarkers research /

Advances in Cancer Biomarkers Research provides a thorough and detailed description of cancer biomarkers for diagnostic, prognostic and therapeutics in several cancer types. The book presents a compendium of topics related to current advanced research, along with fundamental knowledge that will help...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Diğer Yazarlar: Singh, Anand Narayan (Editör), Nayak, Seema (Editör), Rana, Rashmi (Editör)
Materyal Türü: Elektronik Ekitap
Dil:İngilizce
Baskı/Yayın Bilgisi: London, United Kingdom ; San Diego, CA, United States ; Cambridge, MA, United States : Elsevier, Academic Press, an Imprint of Elsevier, [2025]
Konular:
Cancer > Genetic aspects.
Cancer > Molecular aspects.
Biochemical markers.
Biomarkers
Cancer > Aspect génétique.
Cancer > Aspect moléculaire.
Marqueurs biologiques.
Biochemical markers
Cancer > Genetic aspects
Cancer > Molecular aspects
Online Erişim:ScienceDirect
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
İçindekiler:
  • Front Cover
  • Advances in Cancer Biomarkers Research
  • Copyright Page
  • Contents
  • List of contributors
  • 1 Emerging role of biomarker in different cancers
  • 1.1 Introduction
  • 1.2 Categories of biomarkers: Generally five categories of biomarkers
  • 1.3 Biomarkers classification: Biomarkers are classified in following groups
  • 1.4 Biomarkers signatures
  • 1.4.1 Following are signature of biomolecules
  • 1.5 Types of tumor biomarkers
  • 1.6 Diagnostic markers are basically two types
  • 1.6.1 Prognostic marker
  • 1.6.2 Predictive marker
  • 1.7 Uses of tumor biomarkers
  • 1.7.1 Characteristic of ideal tumor marker
  • 1.7.2 Potential biomarkers in peripheral blood for immune response
  • 1.8 Techniques for analyzing biomarkers
  • 1.8.1 DNA and RNA based
  • 1.8.1.1 Polymerase chain reaction
  • 1.8.1.2 In situ hybridization
  • 1.8.1.3 Next generation sequencing
  • 1.8.1.4 Pyrosequencing
  • 1.9 Protein based
  • 1.9.1 Immunohistochemistry
  • 1.10 Molecular pathways in tumor development
  • 1.10.1 TP53/RB pathway
  • 1.10.2 NOTCH pathway
  • 1.10.3 JAK/STAT pathway
  • 1.10.4 RAS/RAF/MAPK pathway
  • 1.10.5 PI3K/Akt/mTOR pathway
  • 1.10.6 Epidermal growth factor receptor pathway
  • 1.10.7 MET pathway
  • 1.11 Biomarkers in different cancers: comprehensive compilation of biomarkers in different cancers are describe in Table 1.1
  • 1.11.1 Biomarkers from brain tumors
  • 1.11.2 Biomarkers for head and neck cancer
  • 1.11.3 Biomarkers for breast cancer
  • 1.11.4 Biomarkers for sarcomas
  • 1.11.5 Biomarkers for lung cancer
  • 1.11.6 Biomarker for colorectal carcinoma
  • 1.11.7 Biomarkers for prostate carcinoma
  • 1.11.8 Biomarkers for female genital organs cancer
  • 1.11.9 Biomarkers for lymphoma and leukaemia
  • 1.12 Conclusion
  • References
  • 2 Role of genetic mechanism in cancer
  • 2.1 Introduction
  • 2.2 DNA repair mechanism in cancer.
  • 2.3 Molecules involved for the DNA damage response
  • 2.4 Genetic mechanism of cancer
  • 2.5 Oncogenes
  • 2.6 Oncogene types and classification
  • 2.7 The role of oncogenes in anticancer therapy
  • 2.8 p53 Tumor suppressor gene
  • 2.9 Noncoding RNAs in cancer
  • 2.10 Role of microRNA in cancer
  • 2.11 Therapeutics in cancer
  • 2.12 Chemotherapy
  • 2.13 Radiotherapy
  • 2.14 Combined radiotherapy and chemotherapy
  • 2.15 Combined radiotherapy and immunotherapy
  • 2.16 Surgical approach
  • 2.17 Targeted therapies
  • 2.18 Conclusion
  • References
  • 3 Role of epigenetics, DNA methylation, histone modification, and microRNA in different cancers
  • 3.1 Introduction
  • 3.1.1 Epigenetic mechanisms
  • 3.1.2 DNA methylation
  • 3.1.3 Histone modification
  • 3.1.4 MicroRNAs
  • 3.1.5 Epigenetic abnormalities in tumorigenesis and development
  • 3.1.5.1 Breast cancer
  • 3.1.5.2 Prostate cancer
  • 3.1.5.3 Lung cancer
  • 3.1.5.4 Colon cancer
  • 3.1.6 Epigenetic therapy and future challenges
  • References
  • 4 Biogenesis of extracellular vesicles and their role in cancer
  • 4.1 Introduction
  • 4.2 Extracellular vesicles classes, biogenesis, and composition
  • 4.3 Biogenesis of extracellular vesicles
  • 4.3.1 Microvesicle biogenesis
  • 4.3.2 Exosome biogenesis
  • 4.3.3 Apoptotic bodies biogenesis
  • 4.4 Tumor microenvironment
  • 4.5 Extracellular vesicles in the microenvironment
  • 4.6 Extracellular vesicles and cancer progression
  • 4.6.1 Extracellular vesicles mediate cancer cell phenotypes
  • 4.7 Extracellular vesicles and tumor angiogenesis
  • 4.8 Extracellular vesicles and metastasis
  • 4.9 Extracellular vesicles and cancer-mediated immunosuppression
  • 4.10 Clinical utility of extracellular vesicles
  • 4.11 Extracellular vesicles as biomarkers
  • 4.12 Extracellular vesicles in drug resistance
  • 4.13 Extracellular vesicles as cancer therapeutic.
  • 5.16 Alternative pathways after signal disruption
  • 5.16.1 Epigenetics pathway
  • 5.17 Conclusion
  • Abbreviations
  • References
  • 6 Theragnostic exosomes in cancer
  • 6.1 Introduction
  • 6.2 Structure and composition of exosomes
  • 6.2.1 Biogenesis of exosomes
  • 6.2.2 Isolation of exosomes
  • 6.2.2.1 Ultracentrifugation techniques
  • 6.2.2.2 Size-based techniques
  • 6.2.2.3 Capture-based techniques
  • 6.2.2.4 Precipitation techniques
  • 6.2.2.5 Microfluidic-based techniques
  • 6.3 Theragnostics applications
  • 6.3.1 Exosomes in therapeutics
  • 6.3.1.1 Drug delivery
  • 6.3.1.2 Antigen delivery
  • 6.3.2 Exosomes in diagnosis
  • 6.3.2.1 Imaging of exosomes
  • 6.3.2.2 Exosome as biomarkers
  • 6.3.3 Translational application
  • References
  • 7 Exosomes: current and novel biomarkers tools for early stage diagnosis of cancer
  • 7.1 Introduction
  • 7.1.1 Functions of exosomes
  • 7.2 Oncologic characterization of exosomes
  • 7.2.1 Exosome composition
  • 7.2.2 Exosome-mediated intercellular communication
  • 7.3 Exosomes as diagnostic and predictive biomarkers for cancer
  • 7.3.1 Nucleic acids in cancer exosomes
  • 7.3.1.1 Exosomal noncoding RNAs/microRNAs
  • 7.3.1.2 Exosomal circRNAs
  • 7.3.2 Proteins in cancer exosomes
  • 7.3.3 Hypoxia
  • 7.4 Exosomes in different cancer
  • 7.5 Conclusion
  • 7.6 Future perspective
  • References
  • 8 Genetic, epigenetic and exosomal biomarkers in neurological malignancies
  • 8.1 Introduction
  • 8.2 Neurological malignancies: an overview
  • 8.2.1 Primary brain tumors
  • 8.2.2 Secondary brain tumors
  • 8.3 Biomarkers: conceptual analysis
  • 8.4 Genetic biomarkers in neurological malignancies
  • 8.5 Epigenetic biomarkers in neurological malignancies
  • 8.6 Histone modifications and mutations
  • 8.7 DNA methylation
  • 8.8 MicroRNAs
  • 8.9 Long noncoding RNAs
  • 8.10 Exosomal biomarkers in neurological malignancies.
  • 8.11 Challenges of biomarkers
  • 8.12 Future prospects and conclusion
  • References
  • 9 Current epigenetic and exosomal biomarkers in head and neck cancers
  • 9.1 Introduction
  • 9.2 Genetic alterations
  • 9.3 Epigenetic alterations
  • 9.4 Promoter hypermethylation
  • 9.5 MicroRNAs (miRNAs) and small interfering RNA (siRNA)
  • 9.6 Histone acetylation
  • 9.7 Exosomes as emerging biomarker in head and neck cancer
  • 9.8 Biogenesis of exosomes
  • 9.9 Isolation of exosomes
  • 9.10 Structure of exosomes
  • 9.11 Potential diagnostic and therapeutic applications of exosomes on HNSCC
  • 9.11.1 Diagnostic approach
  • 9.11.2 Therapeutic approach
  • 9.11.3 Immune modulation
  • 9.11.4 Exosomes as targeted drug delivery
  • 9.11.5 Ongoing clinical trial with exosomes in HNCC
  • 9.12 Conclusion
  • References
  • 10 Role of epigenetics in breast cancer: current status and future perspectives
  • 10.1 Introduction
  • 10.1.1 Types and molecular profiling of breast cancer
  • 10.2 Role of epigenetics in breast cancer
  • 10.2.1 Alterations of breast cancer epigenome
  • 10.2.1.1 DNA methylation
  • 10.2.2 Histone modifications
  • 10.2.3 MicroRNAs
  • 10.2.4 Alterations as tumor microenvironment in breast cancer
  • 10.3 Methods for detection of epigenetic changes
  • 10.4 Epigenetics as biomarkers
  • 10.4.1 Epigenetics as diagnostic and prognostic biomarkers
  • 10.4.2 Epigenetics as predictive biomarkers
  • 10.5 Epigenetics in breast cancer treatment
  • 10.5.1 Epidrugs
  • 10.6 Future perspective
  • 10.7 Conclusion
  • AI disclosure
  • References
  • 11 Role of extracellular vesicles in renal cell carcinoma
  • 11.1 Introduction
  • 11.2 Extracellular vesicles: what's more to these cell mediators?
  • 11.3 Extracellular vesicles biogenesis and secretion
  • 11.4 Extracellular vesicles in renal cell carcinoma
  • 11.5 Immune evasion
  • 11.6 Tumorigenesis
  • 11.7 Tumor metastasis.

Benzer Materyaller